-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The preferred treatment mode for ovarian cancer is cytoreductive surgery combined with platinum-based chemotherapy
Professor Wei Jihong
Wei JihongMaster of Medicine, Sun Yat-sen University
Chief Physician of Gynecology, Jiangmen Central Hospital
Member of the Hysteroscopy Group of the Gynecological Endoscopy Branch of the Guangdong Medical Association
Member of the Female Reproductive Surgery Branch of Guangdong Plastic Surgery Association
Medical status, profession and achievements: 21 years of experience in gynecology, good at standardized diagnosis and treatment of gynecological benign and malignant tumors; good at laparoscopic minimally invasive surgery for gynecological benign and malignant tumors, hysteroscopic minimally invasive surgery for various uterine cavity diseases, and cervical diseases He has rich experience in the diagnosis and treatment of endocrine diseases such as genital malformations, menstrual abnormalities, and infertility
Case sharing
Case sharingone
oneCase review
Case reviewbasic information
basic informationThe patient was a female with a 50-year-old age of onset.
After treatment
After treatmentThe first stage: neoadjuvant chemotherapy + surgery + postoperative chemotherapy
The first stage: neoadjuvant chemotherapy + surgery + postoperative chemotherapyThe patient came to the hospital on June 18, 2020 due to "lower abdominal distension for 1 month"
Gynecological examination revealed: normal vulvovaginal development, mild cervix inflammation, normal uterus size, uterine body palpation is not clear, posterior wall and rectal fossa and nodular induration, left adnexal area palpable and a hard mass about 12× 10×10cm, the border is not clear, the movement is not good, and there is no tenderness; the right appendage is not palpable
Initial diagnosis: ovarian serous papillary carcinoma
NACT uses the TC regimen, and mild liver damage begins to occur after a course of chemotherapy
Evaluation after two passes of NACT, gynecological examination: normal vulvovaginal development, mild cervix inflammation, normal uterine size, posterior wall and rectal fossa and nodular induration, left appendix area and a hard mass, about 5×6× 7cm, the border is not clear, the movement is not good, and there is no tenderness; the right appendage is not palpable
Figure 1.
Figure 1.
The postoperative diagnosis was high-grade serous carcinoma of the ovary stage IIIB; viral hepatitis B (active stage)
Figure 2.
Figure 2.
The second stage: PARP inhibitor maintenance treatment
Genetic testing of the patient after chemotherapy indicated that BRCA1 +, HRD +
Figure 3.
Figure 3.
Figure 4.
Changes in blood routine during maintenance treatment with niraparib
Changes in blood routine during maintenance treatment with niraparib Figure 4.
Changes in blood routine during maintenance treatment with niraparib
Figure 5.
Enhanced CT of the pelvis and abdomen after Nirapali maintenance treatment (2021-06-01)
Enhanced CT of the pelvis and abdomen after Nirapali maintenance treatment (2021-06-01) Figure 5.
Enhanced CT of the pelvis and abdomen after maintenance Nirapali treatment (2021-06-01)
two
twoCase summary
Case summaryThis patient is ovarian serous papillary carcinoma stage IIIB.
When choosing the initial treatment plan, consider the patient's severe tumor burden, low physical status ECOG score, poor surgical tolerance, and difficulty in achieving the ideal reduction.
In order to reduce tumor burden and Difficulty of the operation, NACT treatment is given first
.
The patient has hepatitis B virus, poor resistance, HNV active stage, and severe liver damage after two courses of NACT, so he was treated with entecavir, bicyclol, compound glycyrrhizin, sodium glucuronate and other antiviral and liver protection treatments
.
IDS was performed later, and 4 courses of TC chemotherapy plus liver-protecting antiviral treatment were continued after the operation.
The process went smoothly and the liver function did not appear to be abnormal again
.
After completing the initial treatment, in terms of maintenance treatment, considering that the patient's genetic test is positive for BRCA1, the liver cell function of viral hepatitis B (active phase) is poor, and the condition of the disease is comprehensively evaluated, and the maintenance treatment is selected niraparib
.
It has lasted for more than 9 months.
The tumor markers were rechecked, blood routine and liver function were basically normal, and the patient's quality of life was good
.
No recurrence was seen, and the treatment effect was good
.
Leave a message here